Abstract
SUMMARYBleeding is still a major cause of morbidity and mortality in obstetrics. As recent reports have documented the successful treatment of some cases of postpartum hemorrhage (PPH) refractory to standard treatment with recombinant activated factor VII (rFVIIa), we have performed a systematic review of the existing literature on this topic. Although supported by few and uncontrolled studies, on the whole the published data suggest a potential role of rFVIIa in the management of severe PPH. However, further evidences are needed in order to better assess the optimal dose, the effectiveness and the safety of rFVIIa in such critical bleeding condition.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
